Amniotic mesenchymal stem cell therapy - Amniotics
Alternative Names: AmnioPul-02; PulmoStem™Latest Information Update: 28 Nov 2025
At a glance
- Originator Amniotics
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Idiopathic pulmonary fibrosis; Lung disorders; SARS-CoV-2 acute respiratory disease
Most Recent Events
- 28 Nov 2025 No recent reports of development identified for phase-I development in SARS-COV-2 acute respiratory disease(In the elderly, In adults) in Sweden (Parenteral)
- 28 Aug 2025 No recent reports of development identified for preclinical development in Idiopathic-pulmonary-fibrosis in Sweden (Parenteral)
- 28 Aug 2025 No recent reports of development identified for preclinical development in Lung disorders in Sweden (Parenteral)